Home gilead
 

Keywords :   


Tag: gilead

Premarket Biotech Digest: Gilead HIV, Eliquis Trial Errors, Clinical Trial Phases

2015-08-04 07:51:25| Biotech - Topix.net

This may be FDA 101 for some people, but many lay investors may not be aware of the precise details; so I am providing this brief note following the FDA itself. All new drugs and almost all drugs applying for new indications must go through a clinical research where it is tested in human subjects prior to FDA approval.

Tags: trial errors clinical digest

 

Gilead beats Street 2Q forecasts on surge in sales, profit

2015-07-29 00:40:17| Biotech - Topix.net

Blockbuster hepatitis C medicine Harvoni lifted Gilead Sciences' second-quarter profit by 23 percent as total revenue for the biotech drugmaker jumped 26 percent and it raised its 2015 sales forecast for the second time. Gilead Sciences Inc., based in Foster City, California, said Tuesday that its net income was $4.49 billion, or $2.92 per share.

Tags: sales street profit beats

 
 

Gilead Announces Executive Promotions

2015-07-28 05:55:00| Biotech - Topix.net

Gilead Sciences, Inc. today announced the promotion of William Lee, PhD to Executive Vice President, Research, and Brett Pletcher to Executive Vice President and General Counsel. Dr. Lee and Mr. Pletcher will both join Gilead's senior leadership committee.

Tags: executive promotions announces gilead

 

Gilead Sciences to Release Second Quarter 2015 Financial Results on...

2015-07-22 22:30:04| Biotech - Topix.net

Gilead Sciences, Inc. announced today that its second quarter 2015 financial results will be released on Tuesday, July 28, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the second quarter 2015 and provide a general business update.

Tags: results release financial sciences

 

Premarket Biotech Digest: Is Gilead Undervalued, Oncolytics' Reolysin, Novo Nordisk Reports Results

2015-07-13 18:14:55| Biotech - Topix.net

Gilead Sciences shares have once again seen a pullback in the last three weeks. Since June 24th, the stock is down nearly 7%, presenting another good opportunity to buy.

Tags: results reports novo digest

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »